Comparison
Both are researched for their ability to elevate IGF-1 activity and promote anabolic signalling, but through fundamentally different mechanisms. IGF-1 LR3 directly activates the IGF-1 receptor; MK-677 (ibutamoren) is an oral ghrelin mimetic that raises GH levels, which in turn stimulates endogenous hepatic IGF-1 production. This difference in mechanism produces distinct pharmacological profiles, side effect patterns, and research applications.
MK-677 is a non-peptide small molecule (not a peptide), but is commonly grouped with peptide research compounds due to its GH/IGF-1 axis activity.
| Attribute | IGF-1 LR3 | MK-677 (Ibutamoren) |
|---|---|---|
| Molecular type | Peptide (modified IGF-1 with LR3 extension) | Non-peptide small molecule (ghrelin mimetic) |
| Mechanism | Direct IGF-1 receptor (IGF-1R) agonism; activates PI3K/Akt and MAPK/ERK growth pathways | GHS-R1a (ghrelin receptor) agonism; stimulates pituitary GH release; GH then drives hepatic IGF-1 production (indirect) |
| IGF-1 elevation route | Direct (bypasses GH axis entirely) | Indirect (via GH stimulation and hepatic IGF-1 synthesis) |
| Half-life | ~12–15 hours (LR3 extension reduces IGFBP binding) | ~24 hours (once-daily oral dosing) |
| Route | SubQ or IM injection | Oral (once daily) |
| Commonly reported doses | 20–100 mcg/day SubQ or IM | 10–25 mg/day oral |
| GH axis activity | Suppresses GH secretion (negative feedback via IGF-1) | Elevates GH secretion (the primary mechanism) |
| Hunger stimulation | Minimal | Significant (ghrelin receptor activation increases appetite) |
The most important distinction between IGF-1 LR3 and MK-677 is how they engage the IGF-1 axis. IGF-1 LR3 directly activates the IGF-1 receptor (IGF-1R), bypassing the entire GH axis. It does not need to stimulate GH production; it acts as a substitute for endogenous IGF-1 at the receptor level. Paradoxically, because elevated IGF-1 is a negative feedback signal to the pituitary and hypothalamus, administering exogenous IGF-1 LR3 will suppress endogenous GH secretion, which may reduce endogenous IGF-1 production concurrently. MK-677 takes the opposite approach: it stimulates pulsatile GH secretion from the pituitary, leaving the body to produce its own IGF-1 in response to the elevated GH. This preserves the physiological axis and avoids suppressing endogenous GH.
Delivery route is a major practical difference. MK-677 is an oral small molecule taken once daily without injection; this makes it the most accessible GH/IGF-1 axis research compound by delivery route. IGF-1 LR3 requires injection and has a shorter half-life (~12–15 hours), requiring more frequent administration. The LR3 modification (addition of an Arg-Glu-Ala-Leu tripeptide at the N-terminus and a Glu-to-Arg substitution at position 3) reduces binding to insulin-like growth factor binding proteins (IGFBPs), extending IGF-1 LR3's free bioavailability compared to native IGF-1, which is mostly protein-bound in circulation.
Appetite stimulation is a notable practical difference. MK-677 activates the ghrelin receptor, which not only drives GH secretion but also promotes hunger, a well-documented effect of ghrelin receptor agonism. Many research accounts describe significant appetite increase with MK-677, which may be an advantage (for mass-gaining research) or a confounding variable. IGF-1 LR3 does not activate the ghrelin receptor and does not have this appetite-stimulating effect.
IGF-1 LR3 activates the IGF-1 receptor, a tyrosine kinase receptor that, upon activation, initiates the PI3K/Akt pathway (promoting protein synthesis, anti-apoptosis, glucose uptake) and the MAPK/ERK pathway (promoting proliferation and differentiation). These are the same downstream pathways activated by endogenous IGF-1, but the LR3 modification provides a substantially longer half-life and greater free bioavailability.
MK-677 activates GHS-R1a (the ghrelin receptor) in the pituitary and hypothalamus. This stimulates somatotroph cells to secrete growth hormone in pulses. GH then acts on the liver and peripheral tissues to produce IGF-1, which mediates the anabolic and metabolic effects typically attributed to GH. Unlike GHRPs (peptide ghrelin receptor agonists), MK-677 is orally bioavailable due to its non-peptide small molecule structure.
Research has investigated both compounds for their potential role in:
Additional MK-677-specific research areas:
Commonly reported doses of IGF-1 LR3 range from 20 to 100 mcg per day, administered by subcutaneous or intramuscular injection. Research protocols commonly describe cycles of 4 to 6 weeks followed by breaks. Commonly reported MK-677 doses range from 10 to 25 mg per day taken orally, with 25 mg/day being the most common research dose and the dose used in several published trials. MK-677 is often taken for extended periods (months) given its oral convenience and documented tolerability at 25 mg/day in human trials.
IGF-1 LR3, Reported side effects in research and anecdotal accounts include hypoglycaemia (low blood sugar, particularly if administered without eating), muscle cramps, joint pain, and injection site reactions. The hypoglycaemia risk is a primary safety consideration and reflects IGF-1R's role in glucose regulation via insulin-like signalling.
MK-677, Reported side effects in research and anecdotal accounts include increased appetite (often marked), water retention and mild oedema, joint discomfort (associated with elevated IGF-1), mild insulin resistance at higher doses, and fatigue or lethargy (particularly early in administration). Prolactin elevation has been reported in some accounts but is not consistent. Published clinical trial data at 25 mg/day confirms these effects as the most common.
Combination of IGF-1 LR3 and MK-677 has been reported anecdotally. From a mechanistic standpoint, combining them could produce additive IGF-1 axis effects: MK-677 raises endogenous GH and IGF-1 through the pituitary pathway, while IGF-1 LR3 directly activates IGF-1R independently. However, the direct IGF-1 LR3 administration would suppress endogenous GH (negative feedback), partially counteracting MK-677's mechanism. The net IGF-1R stimulation may be higher than either alone, but the interaction between direct IGF-1R activation and GH axis suppression makes the combination pharmacologically complex. No published co-administration protocol exists.
Research contexts favouring IGF-1 LR3 include investigations specifically into direct IGF-1 receptor biology, research requiring precise control over IGF-1R activation independent of the GH axis, or studies where the GH pituitary pathway should not be engaged as a confounding variable. Its injectable route and shorter cycle requirements make it more suited to focused, shorter-duration research windows.
Research contexts favouring MK-677 include investigations where oral delivery is preferred, where the full GH/IGF-1 axis response (including GH-mediated sleep and bone effects) is the research target, or where extended duration is required. Its published clinical trial data at 25 mg/day provides a stronger human evidence base than IGF-1 LR3, which lacks approved clinical status and has limited published human trial data.
LR3 refers to two modifications to the native IGF-1 sequence: substitution of glutamic acid at position 3 with arginine (the R3 component), and addition of a 13-amino-acid extension at the N-terminus including an arginine (the L component). Together these modifications reduce binding to IGF binding proteins (IGFBPs), which normally sequester most circulating IGF-1 in inactive complexes. Native IGF-1 has a half-life of approximately 10–20 minutes in plasma; the LR3 modification extends this to approximately 12–15 hours.
MK-677 activates the ghrelin receptor (GHS-R1a), and ghrelin is the primary endogenous hunger hormone. Ghrelin levels rise before meals and fall after eating; it signals to the hypothalamus to increase appetite. MK-677's ghrelin receptor agonism produces the same hunger-promoting signal regardless of the body's actual caloric status. This effect is separate from its GH-stimulating activity but is an unavoidable consequence of the receptor it targets.
Yes. Elevated circulating IGF-1 provides negative feedback to the pituitary and hypothalamus, suppressing GH secretion. This is a normal regulatory mechanism. Administering exogenous IGF-1 LR3 sends the same signal, reducing endogenous GH pulses while the exogenous IGF-1 LR3 is active. GH production typically normalises after the IGF-1 LR3 clears. MK-677 does not suppress GH; it stimulates it.
Both compounds can produce water retention, but the mechanism differs slightly. IGF-1 LR3 produces water retention through IGF-1R-mediated effects on sodium and water reabsorption in the kidney. MK-677 produces water retention through both GH effects (GH increases renal sodium retention and promotes IGF-1, which compounds this) and direct ghrelin receptor effects. Anecdotal accounts commonly report water retention as more pronounced and persistent with MK-677 than with IGF-1 LR3 at commonly used doses, though individual variation is significant.